Abstract | OBJECTIVE: Recent studies suggest that the P2Y12 ( P2Y purinoceptor 12) receptor of vascular smooth muscle cells in atherosclerotic plaques aggravates atherosclerosis, and P2Y12 receptor inhibitors such as CDL ( clopidogrel) may effectively treat atherosclerosis. It is imperative to identify an effective biomarker for reflecting the P2Y12 receptor expression on vascular smooth muscle cells in plaques. Approach and Results: We found that there was a positive correlation between the level of circulating sLRP1 (soluble low-density lipoprotein receptor-related protein 1) and the number of LRP1+ α-SMA+ (α-smooth muscle actin), P2Y12+, or P2Y12+ LRP1+ cells in plaques from apoE-/- mice fed a high-fat diet. Furthermore, activation of the P2Y12 receptor increased the expression and shedding of LRP1 in vascular smooth muscle cells by inhibiting cAMP (3'-5'-cyclic adenosine monophosphate)/PKA ( protein kinase A)/SREBP-2 ( sterol regulatory element binding transcription factor 2). Conversely, genetic knockdown or pharmacological inhibition of the P2Y12 receptor had the opposite effects. Additionally, CDL decreased the number of lesional LRP1+ α-SMA+ cells and the levels of circulating sLRP1 by activating cAMP/PKA/SREBP-2 in apoE-/- mice fed a high-fat diet. CONCLUSIONS: Our study suggests that sLRP1 may be a biomarker that reflects the P2Y12 receptor level in plaques and has the potential to be an indicator for administering P2Y12 receptor inhibitors for patients with atherosclerosis.
|
Authors | Jiefang Chen, Shulan Pi, Cheng Yu, Hanqing Shi, Yuxiao Liu, Xiaoqing Guo, Lian Zhou, Yuanyuan Li, Hui He, Yuanpeng Xia, Ling Mao, Bo Hu |
Journal | Arteriosclerosis, thrombosis, and vascular biology
(Arterioscler Thromb Vasc Biol)
Vol. 40
Issue 6
Pg. e166-e179
(06 2020)
ISSN: 1524-4636 [Electronic] United States |
PMID | 32349534
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Actins
- Apolipoproteins E
- Biomarkers
- Low Density Lipoprotein Receptor-Related Protein-1
- P2ry12 protein, mouse
- Purinergic P2Y Receptor Antagonists
- Receptors, Purinergic P2Y12
- Srebf2 protein, mouse
- Sterol Regulatory Element Binding Protein 2
- alpha-smooth muscle actin, mouse
- Clopidogrel
- Cyclic AMP
- Cyclic AMP-Dependent Protein Kinases
|
Topics |
- Actins
(analysis)
- Animals
- Apolipoproteins E
(deficiency, genetics, physiology)
- Biomarkers
(analysis)
- Clopidogrel
(pharmacology)
- Cyclic AMP
(metabolism)
- Cyclic AMP-Dependent Protein Kinases
(metabolism)
- Diet, High-Fat
- Gene Expression
- Gene Knockdown Techniques
- Low Density Lipoprotein Receptor-Related Protein-1
(analysis, blood)
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular
(chemistry, metabolism)
- Plaque, Atherosclerotic
(chemistry, metabolism)
- Purinergic P2Y Receptor Antagonists
(pharmacology)
- Receptors, Purinergic P2Y12
(drug effects, genetics, physiology)
- Signal Transduction
- Sterol Regulatory Element Binding Protein 2
(metabolism)
|